strategic alternatives

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

1 week ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

1 week ago talkbio0Tagged Biotechnology, Goldman Sachs, Ironwood, Phase 3 Clinical Trials, plunge, regulatory hurdle, Short Bowel Syndrome, strategic alternatives, United States Food and Drug Administration

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

2 weeks ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

Lava cuts jobs by 30% after key drug discontinued

2 months ago talkbio0Tagged cash runway, Discontinuation (procedure), LAVA, LAVA-1266, mCRPC, restructuring, strategic alternatives

LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway

Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce

3 months ago talkbio0Tagged biotech closure, financial troubles, Nasdaq, oncology company, strategic alternatives, wind-down operations, workforce termination

biotech closure, oncology company, financial troubles, workforce termination, wind-down operations, Nasdaq delisting, strategic alternatives

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

3 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

3 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.